All In Biotech

Drug Trial Radar · NCT00981045

Evaluation of Efficacy and Safety of Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia and Impaired Renal Function

Randomized Evaluation of Efficacy and Safety of Ferric Carboxymaltose in Patients With Iron Deficiency Anemia and Impaired Renal Function

Last checked: Nov 20, 2026Latest source record: Feb 20, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,561 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,561

Actual

Start

Aug 2009

Primary completion

Jul 2011

Study completion Aug 2011

Sponsor

Lead sponsor
American Regent, Inc.Industry
Sponsor type
Industry
First posted
Sep 22, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to examine the efficacy and safety (cardiovascular) of an investigational intravenous (IV) iron, ferric carboxymaltose (FCM), compared to IV iron sucrose (Venofer) in subjects who have iron deficiency anemia (IDA) and impaired renal function.

Conditions

  • Iron Deficiency Anemia
  • Impaired Renal Function

Interventions

  • Ferric Carboxymaltose (FCM)Drug

    2 doses at 15 mg/kg to a maximum 750 mg per dose for a total maximum cumulative dose of 1500 mg

  • Iron Sucrose (Venofer)Drug

    5 doses of 200 mg for a total cumulative dose of 1000 mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change From Baseline to the Highest Observed Hemoglobin Any Time From Baseline to End of Study.Time frame: Day 56
  2. Proportion of Subjects Experiencing at Least One Event in the Primary Composite Safety Endpoint in the Randomized Population.Time frame: Day 120

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Luitpold Pharmaceuticals, Inc.

    Norristown, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.